WorldCat Identities

عبد الرحمن، عمر

Overview
Works: 32 works in 42 publications in 2 languages and 176 library holdings
Genres: Trials, litigation, etc  Criticism, interpretation, etc 
Roles: Author
Classifications: KRM174.J36, 297.6
Publication Timeline
.
Most widely held works about عبد الرحمن، عمر
 
moreShow More Titles
fewerShow Fewer Titles
Most widely held works by عبد الرحمن، عمر
Mawqif al-Qurʼān min khuṣūmih by ʻUmar ʻAbd al-Raḥmān( Book )

3 editions published in 2006 in Arabic and held by 21 WorldCat member libraries worldwide

Koran; evidence, authority, etc.; apostasy; Islam; apologetic work
The present rulers and Islam : are they Muslims or not by ʻUmar ʻAbd al-Raḥmān( Book )

1 edition published in 1990 in English and held by 7 WorldCat member libraries worldwide

Mīthāq al-ʻamal al-Islāmī by Nājiḥ Ibrāhīm( Book )

1 edition published in 1984 in Arabic and held by 5 WorldCat member libraries worldwide

Kalimat ḥaqq : murāfaʻat ʻAbd al-Raḥmān fī qaḍīyat al-Jihād by ʻUmar ʻAbd al-Raḥmān( Book )

1 edition published in 1985 in Arabic and held by 4 WorldCat member libraries worldwide

Exploring high precision radiotherapy technologies by ʻUmar ʻAbd al-Raḥmān( )

2 editions published in 2013 in English and held by 3 WorldCat member libraries worldwide

CLINICAL ONCOLOGY TIPS AND TRICKS by ʻUmar ʻAbd al-Raḥmān( )

2 editions published in 2013 in English and held by 3 WorldCat member libraries worldwide

Kalima ḥaqq by ʻUmar ʻAbd al-Raḥmān( Book )

1 edition published in 1987 in Arabic and held by 2 WorldCat member libraries worldwide

Exploring systemic options for advanced hepatocellular carcinoma by ʻUmar ʻAbd al-Raḥmān( )

1 edition published in 2013 in English and held by 2 WorldCat member libraries worldwide

Kalimat ḥaqq : murāǧaʻat ʻUmar ʻAbd-ar-Raḥmām fī qaḍīyat al-ǧihād by ʻUmar ʻAbd al-Raḥmān( Book )

2 editions published in 1985 in Arabic and held by 2 WorldCat member libraries worldwide

Impact of prior malignancy on outcomes of stage IV esophageal carcinoma: SEER based study( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

ABSTRACT: Introduction : Usually, clinical trials on esophageal cancer exclude patients with a prior malignancy, assuming that this may influence survival outcomes. However, little is known about the impact of a prior malignancy on its prognosis. Methodology : The Surveillance, Epidemiology, and End Results database (SEER) was used to review patients with stage IV squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the esophagus during 1973–2014. We calculated overall and esophageal cancer-specific survival using unadjusted Kaplan-Meier and multivariable covariate-adjusted Cox models. Results : A total of 7, 807 patients with stage IV SCC, and 11, 238 patients with stage IV AC were reviewed, of which 652 and 840 patients, respectively, had a prior malignancy. Kaplan-Meier curves did not show difference in overall survival of SCC or AC in patients with prior malignancy. Stage IV AC patients with prior malignancy did not show different esophageal cancer-specific survival. However, esophageal cancer-specific survival was better among stage IV SCC patients with prior malignancy. Similar results were observed in Cox models after adjustment for: age, sex, race, marital status, grade, site in esophagus, and undergoing surgery. Conclusion : Prior malignancy does not adversely impact survival of stage IV esophageal cancer. These results should be taken into consideration when designing clinical trials
Mauqif al-Qurʼān min ḫuṣūmihī by ʻUmar ʻAbd al-Raḥmān( Book )

1 edition published in 2006 in Arabic and held by 1 WorldCat member library worldwide

Treatment at a high‐volume centre is associated with improved survival among patients with non‐metastatic hepatocellular carcinoma( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract: Background & Aims: The association between case volume and outcomes is well‐documented for several cancer types. However, it is unknown if patients with hepatocellular carcinoma treated at high‐volume centres have improved overall survival. Methods: About 135442 patients diagnosed with hepatocellular carcinoma between 2004‐2014 were identified in the Commission on Cancer's National Cancer Database and 53795 patients were excluded for metastatic or node‐positive disease. Average annual case volume was calculated as the total number of cases treated per centre from 2004‐2014 and dividing by 10. Receiver operating characteristic curves showed the most significant case number threshold between high‐volume centres and remaining centres. Univariate and multivariate analyses were performed using Cox regression analysis to determine factors associated with improved survival. Kaplan‐Meier curves and log‐rank tests were used for overall survival estimates. Results: A total of 81647 patients with stage I‐III hepatocellular carcinoma were treated at a total of 1218 centres. The median [range] case volume per year averaged over the 10‐year study period was 48.6 [0.1‐205.5]. High‐volume centres treated >114 cases of hepatocellular carcinoma annually while remaining centre treated ≤114 cases. Median survival for patients treated in high‐volume centres and remaining centres were 31.9 and 16.6months respectively (Log Rank P <.001). On multivariate analysis, average annual case volume was significantly associated with improved survival. Conclusions: Receiving treatment at a high‐volume centre is significantly associated with survival for patients with non‐metastatic disease. Improved survival at high‐volume centres may be related to access to a variety of treatment modalities, multidisciplinary evaluation, and/or subspecialty expertise
Validation of the 8th AJCC staging system for gastric cancer in a population-based setting( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

ABSTRACT: Background: The aim of this analysis is to validate the prognostic value of the 8 th  edition of the American Joint Committee on Cancer (AJCC) staging system for gastric cancer. Methods : Through SEER*Stat program, Surveillance, epidemiology and end results database (2010–2013) was accessed and 8th AJCC stages were reconstructed. Cancer-specific survival analyses according to both 7th and 8th editions were conducted through Kaplan-Meier analysis/log-rank testing and multivariate analysis was conducted through a Cox model. Results : Among pathologically-staged patients, P values for pairwise comparisons among different 8th AJCC stages were significant (<0.05) for all comparisons except for stage IIIC vs. IV; while P values for pairwise comparisons among different 7th AJCC stages were significant (<0.05) for all comparisons except for stage IIIA vs. IIIB and stage IIIC vs. IV. Among clinically-staged patients and according to either the clinical 8th AJCC or the 7th AJCC, significant overlap in outcomes existed between different stages. Among pathologically-staged patients, c-statistic for the pathological 8th system was: 0.762; while for the 7th system, it was: 0.763. Among clinically-staged patients, c-statistic for the clinical 8th system was: 0.634; while for the 7th system, it was: 0.637. Conclusion : Compared to the 7th system, the 8th system does not bring about significant prognostic improvement (for either clinically- or pathologically-staged patients)
Kalimat ḥaqq by ʻUmar ʻAbd al-Raḥmān( Book )

1 edition published in 1985 in Arabic and held by 1 WorldCat member library worldwide

Assessment of the external validity of the American Joint Committee on Cancer 8th staging system for anal carcinoma( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract: Background: The current study evaluates the prognostic value of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for patients with anal carcinoma. Patients and methods: The Surveillance, Epidemiology and End Results (SEER) database (2004–2014) was explored and AJCC 6th and 8th stages were formulated. Through Kaplan–Meier analysis, overall survival analyses were performed. The Cox regression model (adjusted for age, gender, histology, ethnicity, subsite and grade) was calculated for cancer-specific survival and, subsequently, pairwise comparisons of hazard ratios were calculated. Results: A total of 11, 934 anal carcinoma patients were included in the analysis. Overall survival was compared according to both AJCC 6th and 8th systems. For both staging systems, the p value for the trend in overall survival was significant ( p  < .0001). Nevertheless, for the AJCC 6th system, stage IIIA and IIIB curves were overlapping; while for the AJCC 8th system, the median survival for stage IIB was lower than the mean survival for stage IIIA (74 months vs. 96 months). Moreover, stage IIIB and stage IIIC curves were overlapping. The cause-specific (cancer-specific) Cox regression hazard was calculated for both staging systems. Pairwise hazard ratio comparisons between different AJCC 6th stages were performed and all p values for comparisons were significant ( p  < .05). Pairwise hazard ratio comparisons between different AJCC 8th stages were performed and only the following comparisons were significant ( p  < .0001) (I vs. IIA; IIA vs. IIB; IIIC vs. IV). The C -statistic (using death from anal carcinoma as the dependent variable) for the AJCC 6th staging system was: 0.681 (SE: 0.009; 95% CI: 0.664–0.698); while the C -statistic for the AJCC 8th staging system was 0.687 (SE: 0.008; 95% CI: 0.670–0.703). Conclusions: There is no evidence of significant improvement in the AJCC 8th edition compared to AJCC 6th (or 7th) edition in terms of overall or cancer-specific survival prediction
Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract: Background and aims: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and its incidence has increased during the past decade. While hepatitis B and C virus infections and alcohol were established risk factors, the impact of smoking on the incidence and mortality of HCC was needed to be confirmed. Methods: We reviewed cohort and case–control studies evaluating the association between cigarette smoking and incidence and mortality of HCC from MEDLINE and Google Scholar. We also checked reference lists of original studies and review articles manually for cross‐references up to February 2016. We extracted the relevant information on participant characteristics and study outcomes, as well as information on the methodology of the studies. We also assessed the quality of the included trials using critical appraisal skills program checklists. Meta‐analysis was performed by using RevMan 5.3 software. Results: A total of 81 studies were included in the systematic review. Pooled OR for HCC development with current smokers was 1.55 (95% CI: 1.46 to 1.65; P < 0.00001). Pooled OR for HCC development with former smokers was 1.39 (95% CI: 1.26 to 1.52; P < 0.00001) and pooled OR for HCC development with heavy smokers was 1.90 (95% CI: 1.68 to 2.14; P < 0.00001). Pooled OR for the mortality of current smokers with HCC was 1.29 (95% CI: 1.23 to 1.34; P < 0.00001); and for former smokers with HCC, it was 1.20 (95% CI: 1.00 to 1.42; P = 0.04). Conclusions: Cigarette smoking increases the incidence and mortality of HCC. Further studies are needed to evaluate possible impact of quitting smoking on decreasing this risk
Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis( )

in English and held by 1 WorldCat member library worldwide

Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show promising results in metastatic breast cancer. However, an increased incidence of adverse events is remarkable. Among others, gastrointestinal (GI) involvement is of momentous impact on patients and their quality of life. Methods: Our search included PubMed, ASCO, ESMO and SABCS databases. Randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors were identified and considered relevant based on providing a sufficient safety profile on the incidence of adverse GI effects. Results: Of the 999 records initially screened for relevance, 33 articles were found relevant and 4 studies were finally eligible for meta-analysis with a total of 2007 patients. The relative risk (RR) for all-grade nausea was 1.48 [95% confidence interval (CI): 1.12–1.93, p = 0.005], vomiting was 1.74 (95% CI: 1.09–2.76, p = 0.02), decreased appetite was 1.42 (95% CI: 1.07–1.88, p = 0.02), and for diarrhea it was 1.44 (95% CI: 1.19–1.74, p = 0.0002). Meanwhile, the RR for high-grade nausea was 1.10 (95% CI: 0.29–4.13, p = 0.89), vomiting was 1.38 (95% CI: 0.25–7.75, p = 0.72), decreased appetite was 4.00 (95% CI: 0.87–18.37, p = 0.07), and high-grade diarrhea was 1.19 (95% CI: 0.44–3.21, p = 0.73). Conclusion: Selective CDK4/6 inhibitors were not associated with higher-grade GI toxicities reflecting a well-tolerated safety profile. Regarding the increase in all-grade GI toxicities, it needs further caution with addition of cytotoxic chemotherapy
al-Taṭwīr al-tiknūlūjī wa-dawruhu fī al-tanāfus al-ṣināʻī by ʻUmar ʻAbd al-Raḥmān( Book )

1 edition published in 1999 in Arabic and held by 1 WorldCat member library worldwide

Kalimat ḥaqq : murāfaʻat al-Duktūr ʻUmar ʻAbd al-Raḥmān fī qaḍīyat al-Jihād by ʻUmar ʻAbd al-Raḥmān( Book )

1 edition published in 1987 in Arabic and held by 1 WorldCat member library worldwide

Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract: Background: Small cell lung cancer (SCLC) is a distinct clinical and pathological entity within the spectrum of lung cancer. It was observed that the relative age distribution of the disease changed over years. Methods: Surveillance, epidemiology, and end results (SEER) database (1973‐2013) was utilized to determine the incidence, presentation and treatment outcomes of elderly patients (>70 years) with SCLC. Join point regression analysis was then conducted to analyze age‐adjusted trends in incidence for the elderly as well as the whole SCLC population. Survival analysis was conducted through Kaplan–Meier analysis. Clinicopathological characteristics and survival outcomes were compared between patients diagnosed at 70‐79 years old and those older than 80 years old (octogenarian group). Results: The proportion of elderly patients among all cases of SCLC increased from 23% in 1975 to 44% in 2010. Moreover, the proportion of elderly female patients among all cases of elderly SCLC increased from 25% in 1975 to 49% in 2010. When categorizing patients into four subgroups "70‐74, " "75‐79, " "80‐84, " and "85+", there was a trend toward a lower cancer‐specific survival with increasing age ( P  < .0001). A limited improvement in 5 year survival was observed during the study period and it is less apparent as the age increases. Conclusion: The proportion of elderly patients among all cases of SCLC has increased over the past 40 years. Further studies are needed to better select appropriate treatments for this subset of patients
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.74 (from 0.42 for Oral histo ... to 0.94 for Kalimat ḥ ...)

Alternative Names
ʻAbd al-Raḥmān, ʻUmar, 1938-

Abdel-Rahman, Omar 1938-

Abdel Rahman, Omar, 1938-2017

Omar Abd al-Rahman religioso egiziano

Omar Abdel Rahman

Omar Abdel-Rahman Egyptian cleric, imprisoned for conspiracy in United States

Omar Abdel-Rahman Egyptian criminal

Omar Abdel-Rahman líder musulmán egipcio condenado a cadena perpetua en EEUU por conspiración sediciosa

Omar Abdel-Rahman theoloog uit Egypte

Ömer Abdurrahman

Umar Abd ar-Rahman ägyptischer Kleriker

Umar Abdulrahman

Умар Абдуррахман

טיוטה:עומאר עבדל רחמן

עומאר עבד א-רחמאן מנהיג מוסלמי וטרוריסט מצרי

خومينى مصر

عبد الرحمن، عمر

عبد الرحمن، عمر، 1938-

عمر عبد الرحمن، 1938-

عمر عبد الرحمن الهی‌دان مصری

عمر عبد الرحمن عالم أزهري مصري

オマル・アブドッラフマーン

奧瑪·阿布圖-拉曼

Languages
Arabic (20)

English (18)